What is this study trying to find out about digestive system cancers?

This study is collecting blood samples from patients with metastatic digestive adenocarcinoma to identify new blood biomarkers that may help personalize cancer treatment. Researchers want to better predict and monitor treatment responses using minimally invasive methods. The Institut du Cancer de Montpellier - Val d'Aurelle is leading this research to improve patient care strategies.

Who may be eligible for this digestive system cancer clinical trial?

Adults aged 18 or older with a confirmed diagnosis of adenocarcinoma in digestive organs such as the colon, pancreas, or stomach may be eligible. Both men and women can participate if they are starting or receiving first or second line metastatic chemotherapy or targeted therapy. Please review eligibility criteria for more details.

Is there any cost to participate in this digestive system cancer clinical trial?

Study-related care, including blood sample collection and all trial visits, is provided at no cost. However, personal travel expenses and other costs may vary and are not guaranteed to be covered by the study.

Actively Recruiting

Phase Not Applicable

Age: 18Years +

All Genders

ID03978078

Development of a Prospective Clinicobiological Database in Metastatic Digestive Cancers

Led by Institut du Cancer de Montpellier - Val d'Aurelle · Updated on 2025-02-12

200

Participants Needed

Research Sites

260 weeks

Total Duration

AI-Summary

What this Trial Is About

Digestive cancers, including colorectal cancer, are a major health concern worldwide, accounting for 30 of all cancers. This research aims to create a collection of blood samples from patients with metastatic digestive adenocarcinoma who are receiving first or second line treatments. The goal is to study blood biomarkers that could help tailor treatments by predicting and monitoring response in a minimally invasive way. Patients in the study will have blood samples collected before starting treatment and then approximately every two months during treatment until it ends. Alongside this biological collection, standardized clinical data will be recorded in a database. This approach focuses on blood rather than tumor tissue, allowing repeated sampling to better understand tumor dynamics and treatment effects. Participants will be involved throughout their treatment period with regular blood draws and clinical data collection. Researchers will measure clinical and biological risk factors related to metastatic digestive cancer over a study period of up to 54 months. This ongoing monitoring aims to support research projects that improve personalized patient management strategies. The study is sponsored by the Institut du Cancer de Montpellier - Val dAurelle.

CONDITIONS

Brief Title

A Clinicobiological Database in Metastatic Digestive Cancers

Who Can Participate

Age: 18Years +

All Genders

Eligibility Criteria

You may qualify if you...

Male or female 18 years old or older
Histological diagnosis of adenocarcinoma in colon, rectum, small intestine, pancreas, stomach, bile duct, or esophagus
Planned to receive or currently receiving first or second line metastatic chemotherapy and/or targeted therapy
Signed informed consent form

You will not qualify if you...

Younger than 18 years old
Non-adenocarcinoma histology
Currently receiving specific treatment in first or second metastatic line
Pregnant or breastfeeding women
Not affiliated with a social security system
Unable to have regular follow-up due to psychological, family, social, or geographical reasons
Enrolled in a Phase I-II therapeutic trial that changes usual management and requires additional blood samples

Research Team

Aurore MOUSSION

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here